Received Jul 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | — |
second dose was given January 22, 2025.; This non-serious case was reported by a nurse via sales rep and described the occurrence of drug dose administration interval too short in a patient who received Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (The patient received their first dose of bexsero September 10th 2024). On 22-JAN-2025, the patient received the 2nd dose of Bexsero. On 22-JAN-2025, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too short (Verbatim: second dose was given January 22, 2025.). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-JUL-2025 Registered nurse reported that the patient received their first dose of Bexsero September 10th, 2024, and the second dose was given January 22, 2025, which led to drug dose administration interval too short. Reporter questioned that did the patient need a third dose. Ongoing, did patients who receive a second dose before the 6th month timeframe, should they get a 3rd dose.